Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Cash from Investing Activities: 2020-2024

Historic Cash from Investing Activities for Taysha Gene Therapies (TSHA) over the last 5 years, with Dec 2024 value amounting to -$363,000.

  • Taysha Gene Therapies' Cash from Investing Activities fell 37.14% to -$48,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$344,000, marking a year-over-year increase of 10.88%. This contributed to the annual value of -$363,000 for FY2024, which is 95.06% up from last year.
  • Latest data reveals that Taysha Gene Therapies reported Cash from Investing Activities of -$363,000 as of FY2024, which was up 95.06% from -$7.4 million recorded in FY2023.
  • In the past 5 years, Taysha Gene Therapies' Cash from Investing Activities registered a high of -$363,000 during FY2024, and its lowest value of -$24.9 million during FY2022.
  • For the 3-year period, Taysha Gene Therapies' Cash from Investing Activities averaged around -$10.9 million, with its median value being -$7.4 million (2023).
  • As far as peak fluctuations go, Taysha Gene Therapies' Cash from Investing Activities crashed by 137.33% in 2021, and later surged by 95.06% in 2024.
  • Over the past 5 years, Taysha Gene Therapies' Cash from Investing Activities (Yearly) stood at -$9.1 million in 2020, then slumped by 137.33% to -$21.6 million in 2021, then dropped by 15.66% to -$24.9 million in 2022, then soared by 70.51% to -$7.4 million in 2023, then surged by 95.06% to -$363,000 in 2024.